Cite
HARVARD Citation
Hardesty, M. et al. (n.d.). 999TiPOVARIO: A single-arm, open-label phase II study of maintenance therapy with niraparib + bevacizumab (bev) in patients (pts) with advanced ovarian cancer (OC) after response to frontline platinum-based chemotherapy (chemo). Annals of oncology. p. . [Online].